ILE-IFE — The Obafemi Awolowo University Teaching Hospital (OAUTH) has shattered a continental medical ceiling, officially launching sub-Saharan Africa’s first-ever immunotherapy clinical trial for colorectal cancer. In a historic move timed to coincide with World Cancer Day on February 4, the hospital unveiled a global partnership that offers Nigerian patients access to cutting-edge, life-saving treatment entirely free of charge.
Professor Olusegun Alatise, a renowned Professor of Surgery at OAU and National Director of the African Research Group for Oncology, announced the breakthrough during a press briefing at the OAUTH complex in Ile-Ife this Wednesday. He revealed that a formidable coalition of experts from OAU, the Lagos University Teaching Hospital (LUTH), and Medserve joined forces with the world-leading Memorial Sloan Kettering Cancer Centre (MSK) in the United States to bring this innovation to Nigerian soil.
This clinical trial introduces a revolutionary treatment known as the PD-1 blockade. Unlike traditional chemotherapy, this immunotherapy empowers a patient’s own immune system to track down and destroy mismatch-repair-deficient colorectal cancer cells. The intervention comes as a critical lifeline for Nigeria, where colorectal cancer rates are surging and fewer than half of diagnosed patients currently survive beyond one year.
Professor Alatise confirmed that the research has secured the full backing of the National Health Research Ethics Committee (NHREC) and the National Agency for Food and Drug Administration and Control (NAFDAC). While MSK serves as the study sponsor and data coordinator, BeOne Medicines will distribute the essential immunotherapy drug, tislelizumab, with BioVentures for Global Health managing the regulatory framework to ensure the trial meets international safety standards.
By launching this trial, OAUTH and its partners are tackling the genetic mutations that often leave Nigerian patients with limited treatment options. This initiative essentially domesticates world-class oncology, proving that Nigerian institutions can lead global research while providing immediate relief to citizens who previously had to look abroad for such advanced care.
Following the successful unveiling, Professor Alatise urged colorectal cancer patients across the country to immediately approach OAUTH, LUTH, or Medserve’s NSIA-Diagnostic Centre in Lagos for enrollment. Eligible participants will receive the sophisticated immunotherapy treatment at no cost, marking a massive shift in the accessibility of high-end cancer care in West Africa.
